MX2022003886A - Dominio extracelular modificado del receptor del factor estimulante de colonias de granulocitos (g-csfr) y citocinas que lo unen. - Google Patents

Dominio extracelular modificado del receptor del factor estimulante de colonias de granulocitos (g-csfr) y citocinas que lo unen.

Info

Publication number
MX2022003886A
MX2022003886A MX2022003886A MX2022003886A MX2022003886A MX 2022003886 A MX2022003886 A MX 2022003886A MX 2022003886 A MX2022003886 A MX 2022003886A MX 2022003886 A MX2022003886 A MX 2022003886A MX 2022003886 A MX2022003886 A MX 2022003886A
Authority
MX
Mexico
Prior art keywords
csfr
variant
cytokine
extracellular domain
receptor
Prior art date
Application number
MX2022003886A
Other languages
English (en)
Inventor
Surjit Bhimarao Dixit
Gesa Volkers
Mario Sanches
Brad Nelson
Megan Fuller
Martin J Boulanger
Bianca Loveless
Original Assignee
Zymeworks Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymeworks Inc filed Critical Zymeworks Inc
Publication of MX2022003886A publication Critical patent/MX2022003886A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464418—Receptors for colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

En el presente documento se describen métodos y composiciones para la activación selectiva de células utilizando pares variantes de receptores de citocinas y citocinas, en donde los receptores de citocinas comprenden un dominio extracelular (ECD) del receptor del factor estimulante de colonias de granulocitos (G-CSFR). En determinadas modalidades, los métodos y composiciones descritos en el presente documento son útiles para la activación exclusiva de células para la terapia de transferencia celular adoptiva. Por lo tanto, se incluyen en el presente documento métodos de producción de células que expresan variantes de receptores que son activadas selectivamente por una citocina que no se une a su receptor nativo. También se describen en el presente documento métodos para tratar a un sujeto que lo necesite, que comprenden administrar al sujeto células que expresan una variante de receptor que comprende un dominio extracelular de G-CSFR y coadministrar una variante de citocina que activa el receptor variante.
MX2022003886A 2019-10-08 2020-10-08 Dominio extracelular modificado del receptor del factor estimulante de colonias de granulocitos (g-csfr) y citocinas que lo unen. MX2022003886A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962912318P 2019-10-08 2019-10-08
PCT/CA2020/051352 WO2021068074A1 (en) 2019-10-08 2020-10-08 Modified extracellular domain of granulocyte colony-stimulating factor receptor (g-csfr) and cytokines binding same

Publications (1)

Publication Number Publication Date
MX2022003886A true MX2022003886A (es) 2022-07-12

Family

ID=75436957

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003886A MX2022003886A (es) 2019-10-08 2020-10-08 Dominio extracelular modificado del receptor del factor estimulante de colonias de granulocitos (g-csfr) y citocinas que lo unen.

Country Status (11)

Country Link
US (1) US20240115603A1 (es)
EP (1) EP4041760A4 (es)
JP (1) JP2022553152A (es)
KR (1) KR20220106966A (es)
CN (1) CN114901684A (es)
AU (1) AU2020362556A1 (es)
BR (1) BR112022006784A2 (es)
CA (1) CA3151471A1 (es)
IL (1) IL291906A (es)
MX (1) MX2022003886A (es)
WO (1) WO2021068074A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021068068A1 (en) * 2019-10-08 2021-04-15 Provincial Health Services Authority Chimeric cytokine receptors
WO2022213208A1 (en) * 2021-04-07 2022-10-13 Provincial Health Services Authority Modified granulocyte colony-stimulating factor (g-csf) and chimeric cytokine receptors binding same
WO2023122725A2 (en) * 2021-12-23 2023-06-29 The Trustees Of The University Of Pennsylvania Controllable stimulation of genetically engineered lymphocytes for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
AU770131B2 (en) * 1999-01-06 2004-02-12 Xencor, Inc. Nucleic acids and proteins corresponding to mutants of G-CSF with granulopoietic activity
AU782580B2 (en) * 2000-01-10 2005-08-11 Maxygen, Inc. G-CSF conjugates
CA2737756A1 (en) * 2008-09-19 2010-03-25 Grant Yonehiro Method for the treatment of radiation-induced neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (g-csf) variant
US9193793B2 (en) * 2011-06-13 2015-11-24 Csl Limited Antibodies against G-CSFR and uses thereof

Also Published As

Publication number Publication date
JP2022553152A (ja) 2022-12-22
AU2020362556A1 (en) 2022-05-12
US20240115603A1 (en) 2024-04-11
CN114901684A (zh) 2022-08-12
WO2021068074A1 (en) 2021-04-15
EP4041760A4 (en) 2023-10-11
EP4041760A1 (en) 2022-08-17
KR20220106966A (ko) 2022-08-01
CA3151471A1 (en) 2021-04-15
IL291906A (en) 2022-06-01
BR112022006784A2 (pt) 2022-09-06

Similar Documents

Publication Publication Date Title
MX2022003886A (es) Dominio extracelular modificado del receptor del factor estimulante de colonias de granulocitos (g-csfr) y citocinas que lo unen.
MX2019010382A (es) Metodo de tratamiento de tumor inmunoterapeutico utilizando un agonista alfa,beta-selectivo del receptor de interleuquina-2 en combinacion con terapia de transferencia celular adoptiva.
PH12019502621A1 (en) Antibody-cytokine engrafted proteins and methods of use in the treatement of cancer
PH12020552138A1 (en) Bcma chimeric antigen receptors and uses thereof
MX2020009309A (es) Composiciones de cartirina y métodos para su uso.
MX2020008333A (es) Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
MY190404A (en) Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
MX2018006778A (es) Composiciones de anticuerpo injertado con citoquina y metodos para su uso en inmunorregulacion.
WO2018157171A3 (en) Compositions, articles of manufacture and methods related to dosing in cell therapy
MX2021006912A (es) Composiciones para la administracion de agentes terapeuticos y metodos de uso y fabricacion de las mismas.
EP4275699A3 (en) Use of the cd2 signaling domain in second-generation chimeric antigen receptors
CN106659757A8 (zh) 白介素2的超级激动剂、部分激动剂和拮抗剂
RU2017145940A (ru) Внутрилегочное введение полинуклеотидных агонистов толл-подобного рецептора 9 для лечения рака легких
MX2020005208A (es) Muteinas de interleucina 2 (il-2) y usos de estas.
MX2020011023A (es) Reprogramación de células t cd4 en células cd8 citotóxicas por expresión forzada de cd8ab y receptores de células t restringidos de clase 1.
MX2022003885A (es) Receptores quimericos de citoquinas.
MX2019003543A (es) Anticuerpos que se fijan al interleucina-2 y sus usos.
MX2021001508A (es) Proteínas de unión multiespecífica que se unen a her2, nkg2d y cd16 y métodos de uso.
WO2018042385A3 (en) Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
MX2020001491A (es) Metodos y composiciones para preparar celulas geneticamente modificadas.
MX2021007692A (es) Proteinas de union anti-pd-1 y metodos de uso de las mismas.
MX2021008772A (es) Composiciones y metodos para la estimulacion de celulas natural killer.
CR20190535A (es) Proteínas de anticuerpo injertadas con citocinas y métodos de uso para trastornos relacionados con el sistema inmunitario
MX2021001524A (es) Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso.
Mortezaee et al. NK and cells with NK-like activities in cancer immunotherapy-clinical perspectives